TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03394430

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients in Group A receive intranasal normal saline before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Patients in Group B receive intranasal 0.25mg/kg midazolam before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients in Group C receive intranasal 1μg/kg dexmedetomidine before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.
Study: NCT02672709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apixaban
Study: NCT02877836

Intervention type: OTHER
Group type: OTHER
Intervention: magnetic resonance imaging (fMRI)
Description: To identify movement-related fMRI activation pattern in dystonic patients in comparison to healthy controls Assessment of white matter integrity in the corticospinal tract in a group og dystonic patients compared with the healthy control group

Intervention type: OTHER
Group type: OTHER
Intervention: magnetic resonance imaging (fMRI)
Description: To identify movement-related fMRI activation pattern in dystonic patients in comparison to healthy controls Assessment of white matter integrity in the corticospinal tract in a group og dystonic patients compared with the healthy control group

Intervention type: OTHER
Group type: OTHER
Intervention: magnetic resonance imaging (fMRI)
Description: To identify movement-related fMRI activation pattern in dystonic patients in comparison to healthy controls Assessment of white matter integrity in the corticospinal tract in a group og dystonic patients compared with the healthy control group

Intervention type: OTHER
Group type: OTHER
Intervention: magnetic resonance imaging (fMRI)
Description: To identify movement-related fMRI activation pattern in dystonic patients in comparison to healthy controls Assessment of white matter integrity in the corticospinal tract in a group og dystonic patients compared with the healthy control group
Study: NCT02271074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point of care CD4 testing
Description: Participants in this arm will receive POC CD4 testing using the PIMA™ CD4 test system. Results will be made available to the participant within 20 to 25 minutes, before the participant leaves the HCT room. Participants will be given a copy of their results, which will be affixed to their referral letter, and they will be educated on the meaning of the CD4 results in relation to their health. This session will only be performed once at the time of issuing POC CD4 results.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point of care CD4 testing
Description: Participants in this arm will receive POC CD4 testing using the PIMA™ CD4 test system. Results will be made available to the participant within 20 to 25 minutes, before the participant leaves the HCT room. Participants will be given a copy of their results, which will be affixed to their referral letter, and they will be educated on the meaning of the CD4 results in relation to their health. This session will only be performed once at the time of issuing POC CD4 results.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point of care CD4 testing
Description: Participants in this arm will receive POC CD4 testing using the PIMA™ CD4 test system. Results will be made available to the participant within 20 to 25 minutes, before the participant leaves the HCT room. Participants will be given a copy of their results, which will be affixed to their referral letter, and they will be educated on the meaning of the CD4 results in relation to their health. This session will only be performed once at the time of issuing POC CD4 results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Facilitation
Description: The goal of this intervention is to provide on-going counselling using a combination of motivational and strengths-based counselling approaches.This is a time limited intervention with a maximum of 5 client sessions over a 90-day period. Participants will also be transitioned out of the intervention upon successful entry into HIV care. Sessions will be done using both face-to-face and telephonic approaches, although the former is more preferred.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transport support
Description: The goal of this intervention is to address one of the most frequently noted structural barrier to entry-into-care in resource constrained settings: prohibitive distance or transport cost to reach a health facility.This is a time limited intervention with a maximum of 3 transport assists for healthcare visits over a 90-day period. Transport assistance is provided in the form of reimbursements to claims submitted by the participant after a self-reported HIV care clinic visits. Participants in this arm, receive their transport support through in-person collection or via cell phone transfer. Transport support amounts are standardised according to geographical area.
Study: NCT02569554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06463922
Description: each subject will receive 4 single oral doses of 100 mg PF-06463922 (treatment A: tablets without food; treatment B: tablets with food; treatment C: tablets without food with rabeprazole; treatment D: oral solution without food). There will be at least 10 days washout period between consecutive PF-06463922 single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: 20 mg daily tablets in the evening for 5 days and Pf-06463922 on the morning of day 6 in treatment C.
Study: NCT02767401

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stenting or balloon expansion
Description: all species of drug-eluting stent ((such as Xience, Endeavor, Taxus, Excel, Firebird) implantation or balloon expansion (POBA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc
Description: Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
Study: NCT05334537

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Ninety-six patients aged between 18 and 45 years, with a height of ≥156 centimeters (cm), and a gestational age of \>37 weeks, in the ASA II risk group, who were scheduled for elective CS under spinal anesthesia, were included in the study. Patients who were to undergo lavender aromatherapy with an oxygen mask after the birth of the baby were randomly divided into two groups: aromatherapy (A) (n=48) and control (C) (n=48), who inhaled odorless essential oil. Participants were admitted to the preoperative preparation room 20 min before the operation, and their age, height, weight, and ASA risk scores were recorded after their informed consent was obtained. They were monitored and sent to the operating room after their baseline anxiety levels were measured and recorded using the Visual Analog Scale (VAS) for pain and State-Trait Anxiety Inventory (STAI-I).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil (odorless baby oil- jojoba and almond oil)
Description: Ninety-six patients aged between 18 and 45 years, with a height of ≥156 centimeters (cm), and a gestational age of \>37 weeks, in the ASA II risk group, who were scheduled for elective CS under spinal anesthesia, were included in the study. Patients who were to undergo lavender aromatherapy with an oxygen mask after the birth of the baby were randomly divided into two groups: aromatherapy (A) (n=48) and control (C) (n=48), who inhaled odorless essential oil. Participants were admitted to the preoperative preparation room 20 min before the operation, and their age, height, weight, and ASA risk scores were recorded after their informed consent was obtained. They were monitored and sent to the operating room after their baseline anxiety levels were measured and recorded using the Visual Analog Scale (VAS) for pain and State-Trait Anxiety Inventory (STAI-I).
Study: NCT03357952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive daratumumab 16 milligram per kilogram (mg/kg) intravenously (IV) once every week for 8 weeks (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive daratumumab 16 milligram per kilogram (mg/kg) intravenously (IV) once every week for 8 weeks (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63723283
Description: Participants will receive JNJ-63723283 240 mg IV during Week 1 on Cycle 1 Day 2, Cycle 1 Day 15, then every 2 weeks thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63723283
Description: Participants will receive JNJ-63723283 240 mg IV during Week 1 on Cycle 1 Day 2, Cycle 1 Day 15, then every 2 weeks thereafter.
Study: NCT01297413

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic adult mesenchymal bone marrow stem cells
Description: Patients will receive intravenously one dose of 0.5-1.5 million cells per kg of allogeneic adult mesenchymal bone marrow stem cells
Study: NCT03445923

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Time lapse monitoring (KID Score)
Description: The unique information that is obtainable from taking Pictures each 10 minutes throughout the development of the embryos will be used in the form of a special score (KID score). The score is comprised out of several key developmental parameters.
Study: NCT02463825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimozide 2 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimozide 4 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Lactose tablet)
Study: NCT01956500

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Instaflex
Description: The Instaflex supplement contained the following ingredients (in 3 capsules): Glucosamine sulfate (1500 mg), methylsulfonylmethane (MSM) (500 mg), white willow bark extract (standardized to 15% salicin) (250 mg), ginger root concentrate (50 mg), boswella serrata extract (standardized to 65% boswellic acid) (125 mg), turmeric root extract (50 mg), cayenne 40m H.U. (50 mg), and hyaluronic acid (4.0 mg).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules will contain magnesium stearate, an inert substance.
Study: NCT03080688

Intervention type: DEVICE
Intervention: Prizma Oxygen Saturation Measurement
Description: A radial arterial cannula was placed in either the left or right wrist of each subject.~Blood gas analysis to determine oxyhemoglobin saturation was performed on an OSM-3® multi-wavelength oximeter (Hemoximeter, Radiometer, Copenhagen). No subject was anemic (Hemoglobin ≤ 10gm•dl-1).
Study: NCT00105950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Tyrosine kinase inhibitor administered daily at 1500 mg/kg
Study: NCT04086654

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: International Trauma Interview (ITI) for ICD-11 PTSD and Complex PTSD - German version
Description: The ITI consists of 18 items and for each symptom, standardized questions as well as probes are presented. A trained professional rates both symptom frequency and intensity, which are converted into an overall index of symptom severity. A diagnosis of PTSD/CPTSD is established by applying the ICD-11 diagnostic rules. It takes approximately 30-60 minutes to administer.
Study: NCT04169386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK102
Description: AK102 single dose administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK102
Description: AK102 single dose administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK102
Description: AK102 single dose administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK102
Description: AK102 single dose administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single dose administered subcutaneously
Study: NCT02027701

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro20
Study: NCT04024774

Intervention type: BIOLOGICAL
Intervention: Biological samples
Description: blood samples, urine samples, tissue samples

Intervention type: GENETIC
Intervention: Genetic test
Description: anamnesis and NGS sequencing
Study: NCT00286078

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Precision
Description: Implantable neurostimulator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision
Description: Implantable neurostimulator
Study: NCT00820027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg
Description: One 90 mg tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Description: Two 60 mg tablets once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: One tablet three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo for Etoricoxib 120 mg
Description: Two tablets once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching Placebo for Etoricoxib 120 mg
Description: Two tablets once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for Etoricoxib 120 mg
Description: Two tablets once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo for Etoricoxib 90 mg
Description: One tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching Placebo for Etoricoxib 90 mg
Description: One tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for Etoricoxib 90 mg
Description: One tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo for Ibuprofen
Description: One tablet three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo for Ibuprofen
Description: One tablet three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for Ibuprofen
Description: One tablet three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: As needed via patient-controlled analgesia (PCA) device or as a bolus intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: As needed via patient-controlled analgesia (PCA) device or as a bolus intravenous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: As needed via patient-controlled analgesia (PCA) device or as a bolus intravenous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: As needed via patient-controlled analgesia (PCA) device or as a bolus intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 5 mg as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 5 mg as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 5 mg as needed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: 5 mg as needed
Study: NCT02796820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier Granule
Description: Huaier Granule is continuously taken three times per day, 20g per time.
Study: NCT02051270

Intervention type: OTHER
Intervention: Descriptive study
Description: More than 65 years old elders
Study: NCT03629951

Intervention type: DRUG
Intervention: Oral Antipsychotics (OAP)
Description: This is an observational study. Participants enrolled in this study will continue to receive routine treatment of OAPs for example, risperidone (1 to 6 mg OD to BID), olanzapine (5 to 20 mg OD), haloperidol (5 to 20 mg OD to TID) etc, as directed by their treating physician.
Study: NCT04392453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic therapy
Description: The treatment with the robot Icone will include 30 sessions, each session lasting 45 minutes, with a frequency from three to five times a week. The treatment will be provided in the patient's room. Patients will execute upper limb movement involving elbow flexion-extension, shoulder protraction-retraction, internal-external rotation, flexion-extension, and abduction-adduction. Visual and auditory feedback will be provided during the tasks. The exercises will train both motor and cognitive functions.
Study: NCT04227548

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: needle electromyography
Description: Direct muscle stimulation was performed to deltoid and tibialis anterior muscles with a monopolar needle electrode. Recording was made with a concentric needle electrode.
Study: NCT02053987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation in the home.
Study: NCT03493841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha Lipoic Acid
Description: Lipoic acid is an over the counter supplement. Two different forms, R and racemic are available. R-lipoic acid is the naturally occurring form. Racemic lipoic acid is the most commonly available supplement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha Lipoic Acid
Description: Lipoic acid is an over the counter supplement. Two different forms, R and racemic are available. R-lipoic acid is the naturally occurring form. Racemic lipoic acid is the most commonly available supplement.
Study: NCT04201756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: ①Neoadjuvant treatment stage: the enrolled patients take afatinib at a dosage of 40mg per day, 8-16 weeks in total; and receive CT scan re-examination in the 4th/8th/12th post-therapy week.~②Surgical treatment stage: the patients who respond to alfatinib treatment (CR+PR) and the patients who do not respond to alfatinib therapy but could still undergo surgery (SD and PD) will receive radical lung lobectomy+systematic lymph node dissection.~③Adjuvant treatment stage: The CR, PR and SD patients who have been treated surgically will take alfatinib at a dosage of 40mg per day for at least 1 year. The SD and PD patients who could not receive operation and the PD patients who have received operation will be transferred into medical oncology or/and radiation oncology and receive comprehensive therapy (chemotherapy or/and radiotherapy, the regimen is designed by oncologist and radiologist)
Study: NCT01324323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: 14 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg oral once daily on Days 4-8
Study: NCT00509587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01869257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triclosan coated suture
Description: The patients in the treated arm will have the abdominal wound sutured with triclosan-coated suture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: regular suture
Description: The control arm will have the abdominal wound sutured with a regular non-coated suture
Study: NCT04129918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: light and sound modification (earplugs and eye masks)
Description: In the experimental group，the patients used earplugs and eye masks during nighttime sleep.
Study: NCT01892137

Intervention type: DRUG
Group type: OTHER
Intervention: Ingenol mebutate gel 0.05%
Description: Once daily for 2 consecutive days
Study: NCT00153361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discussion Group

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Discussion Group
Study: NCT02767375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin(OXA), 5-fluorouracil (5-FU)
Description: for the HAIC treatment group OXA 85mg/m2, d1，0-4h 5-FU 1500mg/m2 d1, 4-24h 24 hours in d1 \& 2 , IA，q4-6 Weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatic arterial catheter implantation
Description: for the the HAIC treatment group: Hepatic arterial catheter implantation for HAIC
Study: NCT03240913

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Baseline and Follow-up Surveys
Description: (completed online)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline and Follow-up Surveys
Description: (completed online)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Reported Outcome Measure informed Decision Aid
Description: (PROM-DA)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pamphlet
Description: (usual care)